Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

Navarese, E., Buffon, A. M. T., Kozinski, M., Obonska, K., Rychter, M., Kunadian, V., Austin, D., De Servi, S., Sukiennik, A., Kubica, J., A critical overview on ticagrelor in acute coronary syndromes, <<QJM-AN INTERNATIONAL JOURNAL OF MEDICINE>>, 2013; 106 (2): 105-115. [doi:10.1093/qjmed/hcs187] [http://hdl.handle.net/10807/57496]

A critical overview on ticagrelor in acute coronary syndromes

Buffon, Antonino Maria Tommaso;
2013

Abstract

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
2013
Inglese
Navarese, E., Buffon, A. M. T., Kozinski, M., Obonska, K., Rychter, M., Kunadian, V., Austin, D., De Servi, S., Sukiennik, A., Kubica, J., A critical overview on ticagrelor in acute coronary syndromes, <<QJM-AN INTERNATIONAL JOURNAL OF MEDICINE>>, 2013; 106 (2): 105-115. [doi:10.1093/qjmed/hcs187] [http://hdl.handle.net/10807/57496]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/57496
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact